SAN DIEGO, CA — March 3, 2026 — Leads & Copy —
VivoSim Labs, Inc. (Nasdaq: VIVS) has appointed Dr. Arumugham (Ragoo) Raghunathan as Vice President of Global Sales, the company announced. Based in the Greater Boston area, Raghunathan will spearhead commercial expansion and forge strategic partnerships with biopharma innovators, established pharmaceutical companies, CROs/CDMOs, and research institutions.
Dr. Raghunathan will focus on delivering VivoSim’s liver and gastrointestinal (GI) toxicity solutions. The company aims to enable earlier de-risking of drug candidates and clearer feasibility decisions throughout the development process.
Tony Lialin, Chief Commercial Officer of VivoSim, emphasized Dr. Raghunathan’s ability to build and strengthen relationships through scientific rigor and a focus on outcomes. Lialin said customers instantly trust Raghunathan as a long-term partner because he understands how discovery, DMPK, and safety teams operate under real-world timelines and constraints. Lialin added that Dr. Raghunathan will be instrumental in helping partners generate clearer, earlier signals so they can move forward with the best programs with confidence, maximizing both cost and time efficiency.
VivoSim will intensify engagement with customers who need stronger human relevance and sharper predictivity in preclinical development. This includes discovery and translational teams, preclinical safety, toxicology, and DMPK groups, biotech startups and emerging pharma, large pharma portfolios, CROs/CDMOs and strategic partners, and academic medical centers and research institutes.
VivoSim’s portfolio supports safety assessment programs focused on liver toxicity, including drug-induced liver injury (DILI) risk, and GI toxicity. The company said it enables teams to interrogate potential liabilities with models and readouts designed to better reflect human biology, which is particularly valuable for programs where traditional approaches can obscure or miss risk signals entirely.
Dr. Raghunathan noted the demand for better prediction of liver and GI liabilities, especially as drug modalities diversify and development timelines compress. He said he is excited to help customers translate VivoSim’s science into concrete wins, including smarter prioritization, fewer late-stage surprises, and faster progress to the clinic.
Dr. Raghunathan will also support VivoSim’s broader business and strategic initiatives, including key account development, bespoke partnership plans, and customer success programs designed to move engagements from pilot studies to long-term collaborations.
VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company focused on providing testing of drugs and drug candidates in 3D human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (NAM) models.
The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration (FDA) announcement on April 10, 2025, to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA.
Source: VivoSim Labs
